Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Brouwer

Showing results (1-10 of 215) with videos related to

Pageof 22
Sort By:
Rheumatology (Oxford, England)|January 30, 2020
What can negative temporal artery biopsies tell us?Sarah L Mackie, Elisabeth Brouwer
Rheumatology (Oxford, England)|March 12, 2025
Highlights from the breakout session: novel biomarkers of clinical interest for vasculitisNanthicha Inrueangsri, Mark A Little, Elisabeth Brouwer
European Heart Journal. Cardiovascular Imaging|October 27, 2020
Pulmonary artery activity in Takayasu's arteritis, a role for [18F]FDG PET/CT?Riemer H J A Slart, Elisabeth Brouwer
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2022
Tocilizumab in Giant Cell Arteritis: Better Understanding the BenefitsFrank Buttgereit, Andriko Palmowski, Idil Esen, et al.
The Journal of Rheumatology|May 3, 2019
Methotrexate in Giant Cell Arteritis Deserves a Second Chance - A High-dose Methotrexate Trial Is NeededElisabeth Brouwer, Kornelis S M VAN DER Geest, Maria Sandovici
Current Opinion in Rheumatology|March 15, 2014
Clinical studies on bone-related outcome and the effect of TNF-α blocking therapy in ankylosing spondylitisSuzanne Arends, Anneke Spoorenberg, Elisabeth Brouwer, et al.
Rheumatology (Oxford, England)|February 19, 2026
Polymyalgia rheumatica in transition: is clinical practice finally changing?Kornelis S M van der Geest, Elisabeth Brouwer, Maria Sandovici
Arthritis Research & Therapy|October 18, 2023
High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritisLiseth de Wolff, Suzanne Arends, Elisabeth Brouwer, et al.
RMD Open|February 12, 2022
Need and value of targeted immunosuppressive therapy in giant cell arteritisMaria Sandovici, Niels van der Geest, Yannick van Sleen, et al.
RMD Open|July 28, 2023
External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinicMarieke van Nieuwland, Lenny van Bon, Marloes Vermeer, et al.
Pageof 22

Showing results (1-10 of 215) with videos related to

Sort By:
Pageof 22
Rheumatology (Oxford, England)|January 30, 2020
What can negative temporal artery biopsies tell us?Sarah L Mackie, Elisabeth Brouwer
Rheumatology (Oxford, England)|March 12, 2025
Highlights from the breakout session: novel biomarkers of clinical interest for vasculitisNanthicha Inrueangsri, Mark A Little, Elisabeth Brouwer
European Heart Journal. Cardiovascular Imaging|October 27, 2020
Pulmonary artery activity in Takayasu's arteritis, a role for [18F]FDG PET/CT?Riemer H J A Slart, Elisabeth Brouwer
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2022
Tocilizumab in Giant Cell Arteritis: Better Understanding the BenefitsFrank Buttgereit, Andriko Palmowski, Idil Esen, et al.
The Journal of Rheumatology|May 3, 2019
Methotrexate in Giant Cell Arteritis Deserves a Second Chance - A High-dose Methotrexate Trial Is NeededElisabeth Brouwer, Kornelis S M VAN DER Geest, Maria Sandovici
Current Opinion in Rheumatology|March 15, 2014
Clinical studies on bone-related outcome and the effect of TNF-α blocking therapy in ankylosing spondylitisSuzanne Arends, Anneke Spoorenberg, Elisabeth Brouwer, et al.
Rheumatology (Oxford, England)|February 19, 2026
Polymyalgia rheumatica in transition: is clinical practice finally changing?Kornelis S M van der Geest, Elisabeth Brouwer, Maria Sandovici
Arthritis Research & Therapy|October 18, 2023
High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritisLiseth de Wolff, Suzanne Arends, Elisabeth Brouwer, et al.
RMD Open|February 12, 2022
Need and value of targeted immunosuppressive therapy in giant cell arteritisMaria Sandovici, Niels van der Geest, Yannick van Sleen, et al.
RMD Open|July 28, 2023
External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinicMarieke van Nieuwland, Lenny van Bon, Marloes Vermeer, et al.
Pageof 22